Abstract: Objective To evaluate the efficacy and toxicities of recombinant human endostatin（endostar） combined with chemotherapy for the treatment of liver metastasis of rectal cancer. Methods Endonstar combined with routine chemotherapy agents were administrated to 40 cases with live metastasis of rectal cancer confirmed by histopathology or cytopathology. Endostar of 15mg／d solved in 500ml normal saline was slowly intravenously dropped from day 1 to day 14, and 21 days was a cycle. The chemotherapy agents including FOLFOX 6，FOLFIRI and CapeOX regimens were selected to be given simultaneously. The efficacy was evaluated strictly according to RECIST 1.0 criteria and the toxicity was evaluated according to WHO anti-cancer drug toxicity levels. The long-term efficacy was evaluated according to progression free survival（PFS） and overall survival（OS）. Results The efficacy and toxicity could be evaluated in 40 patients. Of the 40 patients，3 patients achieved CR，9 cases had PR，14 cases had SD, and 14 cases had PD. The response rates was 30.0％ and disease control rate was 65.0％. The median PFS was 8.6 months and the median OS was 17.8 months. The major toxicities were myelosuppression and digestive reaction. Some patients were received neurotoxicity and handfoot syndrome，mainly in grade 1-2. Conclusion Endostar combined with chemotherapy for liver metastasis of rectal cancer has good efficacy and the toxicity is tolerable, which is worth to use in clinic.